Get to know our clinical trials
Clinical trial of PHN-012 in patients with advanced solid tumors.
THE PRIMARY OBJECTIVE IS TO DETERMINE THE MTD OR MAD FOR INTRAVENOUS PHN-012 MONOTHERAPY AND TO EVALUATE ITS SAFETY AND TOLERABILITY.
Technical Summary
- A PHASE I, FIRST-IN-HUMAN STUDY OF PHN-012, AN ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2025-523756-31-00
- Protocol number: PHN-012-001
- Promoter: Pheon Therapeutics Ltd
- Molecule/Drug: PHN-012
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.